Table 1.
CRP (mg/l) | CEA (ng/ml) | SCC‐Ag (ng/ml) | ||||||||
---|---|---|---|---|---|---|---|---|---|---|
Median | Range | P‐value | Median | Range | P‐value | Median | Range | P | ||
Group tested | Esophageal cancer (n = 53) | 10.7A | 5.0–149.5 | <0.001* | 2.5A | 0.4–40.4 | <0.001* | 1.3A | 0.4–34.5 | 0.015* |
Control group (n = 90) | 5.0 | 0.1–13.9 | 0.8 | 0.1–11.4 | 1.0 | 0.6–4.0 | ||||
Type of cancer | Adenocarcinoma (n = 23) | 6.2A | 5.0–45.5 | 0.112 | 2.5A | 0.4–40.4 | 0.865 | 0.9 | 0.4–4.5 | <0.001* |
Planoepitheliale (n = 30) | 14.7A | 5.0–149.5 | 2.4A | 0.4–8.5 | 1.5A | 0.6–34.5 | ||||
TNM stage | I + IIa + IIb (n = 13) | 5.0A | 5.0–64.9 | 0.064 | 1.8**, A | 0.4–3.3 | 0.026* | 1.0 | 0.8–4.3 | 0.264 |
III (n = 30) | 10.1A | 5.0–134.8 | 2.9A | 0.4–40.4 | 1.3 | 0.4–8.2 | ||||
IV (n = 10) | 32.1A | 5.0–149.5 | 2.8A | 0.4–7.8 | 5.3A | 0.5–34.5 | ||||
Depth of tumor invasion (T factor) | T1 + T2 (n = 9) | 5.0A | 5.0–45.5 | 0.295 | 1.8 | 0.4–5.0 | 0.163 | 1.0 | 0.9–24.4 | 0.998 |
T3 (n = 27) | 9.4A | 5.0–79.9 | 2.5A | 0.8–40.4 | 1.2 | 0.4–34.5 | ||||
T4 (n = 17) | 20.9A | 5.0–149.5 | 3.1A | 0.4–23.8 | 1.5 | 0.5–19.6 | ||||
Nodal involvement (N factor) | N0 (n = 13) | 5.0A | 5.0–64.9 | 0.043* | 1.9A | 0.4–3.3 | 0.017* | 1.0 | 0.8–4.3 | 0.702 |
N1 (n = 40) | 14.3A | 5.0–149.5 | 2.9A | 0.4–40.4 | 1.3A | 0.4–34.5 | ||||
Distant metastases (M factor) | M0 (n = 43) | 6.6A | 5.0–134.8 | 0.039* | 2.5A | 0.4–40.4 | 0.918 | 1.2 | 0.4–8.2 | 0.111 |
M1 (n = 10) | 32.1A | 5.0–149.5 | 2.8A | 0.4–7.8 | 5.3A | 0.5–34.5 | ||||
Differentiation of tumor | G1 (n = 10) | 7.7A | 5.0–79.9 | 0.477 | 2.1A | 0.5–7.8 | 0.523 | 1.2 | 0.9–4.5 | 0.507 |
G2 (n = 25) | 6.6A | 5.0–149.5 | 2.6A | 0.5–40.4 | 1.4 | 0.4–19.6 | ||||
G3 (n = 16) | 22.1A | 5.0–75.5 | 2.4A | 0.4–23.8 | 1.1 | 0.5–34.5 | ||||
Survival of patients | Alive (n = 27) | 5.0A | 5.0–79.9 | 0.009* | 2.5A | 0.4–40.4 | 0.728 | 1.2 | 0.4–4.3 | 0.127 |
Died of cancer (n = 26) | 21.1A | 5.0–149.5 | 2.2A | 0.4–23.8 | 1.5A | 0.5–34.5 |
*Statistically significant when P < 0.05.
**Statistically significant in post hoc Dwass‐Steel‐Critchlow‐Fligner test in comparison with stage III (P = 0.019).
Statistically significant in comparison with control group.